Discontinuation syndrome associated with paroxetine in depressed patients a retrospective analysis of factors involved in the occurrence of the syndrome

CNS Drugs

Volumn 20, Issue 8, 2006, Pages 665-672

  Himei, Akio ^a,b   Okamura, Takehiko ^a,b  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Osaka Institute of Social Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; CONTROLLED STUDY; DEPRESSION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHI-SQUARE DISTRIBUTION; DEPRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; RETROSPECTIVE STUDIES; SEX FACTORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33746535455     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620080-00005     Document Type: Review

References (18)

1. Tamam L, Ozpoyraz N. Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv Ther 2002; 19 (1): 17-26
2. Fava GA, Ruini C, Sonino N. Treatment of recurrent depression: a sequential psycotherapeutic and psychopharmacological approach. CNS Drugs 2003; 17 (15): 1109-17
3. Ables AZ, Baughman III OL. Antidepressants: update on new agents and indications. Am Fam Physician 2003; 67 (3): 547-54
4. Olver JS, Burrows GD, Norman TR. Discontinuation syndromes with selective serotonin reuptake inhibitors: are there clinically relevant differences? CNS Drugs 1999; 12 (3): 171-7
5. Black K, Shea C, Dursun S, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000; 25 (3): 255-61
6. Lejoyeux M, Ades J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 1997; 58 Suppl. 7: 11-6
7. Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol 1998; 12 (3): 305-13
8. Price JS, Waller PC, Wood SM, et al. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42 (6): 757-63
9. Ditto KE. Discontinuation syndrome: awareness as an approach to prevention. Postgrad Med 2003; 114 (2): 79-84
10. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 1997; 58 Suppl. 7: 17-22
11. Therrien F, Markowitz JS. Selective serotonin reuptake inhibitors and withdrawal symptoms: a review of the literature. Hum Psychopharmacol 1997; 12: 309-23
12. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44 (2): 77-87
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
14. Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry 1997; 58 Suppl. 7: 37-40
15. Green B. Focus on paroxetine. Curr Med Res Opin 2003; 19 (1): 13-21
16. Golden RN. Selective serotonin reuptake inhibitor elimination half-lives: the long and the short of it. Biol Psychiatry 1998; 44: 75-6
17. Pyke RE. Paroxetine withdrawal syndrome. Am J Psychiatry 1995; 152 (1): 149-50
18. Schatzberg AF, Haddad P, Kaplan EM, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. J Clin Pharmacol 1996; 42 (6): 757-63